FAM83H-AS1 is associated with clinical progression and modulates cell proliferation, migration, and invasion in bladder cancer

被引：28

作者：

Shan, Hui ^{[1
]}

Yang, Yunbo ^{[2
]}

Zhu, Xuhui ^{[1
]}

Han, Xiuwu ^{[1
]}

Zhang, Peng ^{[1
]}

Zhang, Xiaodong ^{[1
]}

机构：

[1] Capital Med Univ, Beijing Chaoyang Hosp, Dept Urol, 8 Gongren Tiyuchang Rd South, Beijing 100020, Peoples R China

[2] Hebei Yanda Hosp, Dept Urol, Langfang, Hebei, Peoples R China

来源：

JOURNAL OF CELLULAR BIOCHEMISTRY | 2019年 / 120卷 / 03期

关键词：

biomarker; bladder cancer; FAM83H-AS1; long noncoding RNA (lncRNA); LONG NONCODING RNA; LNCRNA FAM83H-AS1; STATISTICS; EXPRESSION; APOPTOSIS;

D O I：

10.1002/jcb.27758

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

FAM83H-AS1, also known as oncogenic long noncoding RNA (lncRNA)-3, is a novel lncRNA that has been suggested to be dysregulated in a variety of human cancers. However, the expression status and function of FAM83H-AS1 in bladder cancer are still unknown. The object of our study is to explore the clinical value of FAM83H-AS1 in patients with bladder cancer and the biological function of FAM83H-AS1 in bladder cancer cells. In our results, the expression of FAM83H-AS1 was obviously elevated in bladder cancer tissue samples and bladder cancer cell lines compared with adjacent normal tissue samples and normal bladder epithelial cell lines, respectively. In addition, high expression of FAM83H-AS1 was associated with advanced clinical stage and the presence of muscularis invasion and served as an independent poor prognostic factor for overall survival in patients with bladder cancer. The loss-of-function study showed that silencing FAM83H-AS1 expression suppressed cell proliferation, migration, and invasion and induced cycle arrest at G0/G1 phase. In conclusion, FAM83H-AS1 is involved in the progression of bladder cancer and serves as a prognostic biomarker and potential therapeutic target for patients with bladder cancer.

引用

页码：4687 / 4693

页数：7

共 22 条

[1]

[Anonymous], GUT

[2]

[Anonymous], J CELL PHYSL

[3] Aberrant expression of PlncRNA-1 and TUG1: potential biomarkers for gastric cancer diagnosis and clinically monitoring cancer progression [J].

Baratieh, Zohreh ;

Khalaj, Zahra ;

Honardoost, Mohammad Amin ;

Emadi-Baygi, Modjtaba ;

Khanahmad, Hossein ;

Salehi, Mansoor ;

Nikpour, Parvaneh .

BIOMARKERS IN MEDICINE, 2017, 11 (12) :1077-1090

[4] Pan-cancer transcriptome analysis reveals long noncoding RNAs with conserved function [J].

Cabanski, Christopher R. ;

White, Nicole M. ;

Dang, Ha X. ;

Silva-Fisher, Jessica M. ;

Rauck, Corinne E. ;

Cicka, Danielle ;

Maher, Christopher A. .

RNA BIOLOGY, 2015, 12 (06) :628-642

[5] The prognostic role of epigenetic dysregulation in bladder cancer: A systematic review [J].

Casadevall, David ;

Kilian, Angs Yacine ;

Bellmunt, Joaquim .

CANCER TREATMENT REVIEWS, 2017, 61 :82-93

[6] Cancer Statistics in China, 2015 [J].

Chen, Wanqing ;

Zheng, Rongshou ;

Baade, Peter D. ;

Zhang, Siwei ;

Zeng, Hongmei ;

Bray, Freddie ;

Jemal, Ahmedin ;

Yu, Xue Qin ;

He, Jie .

CA-A CANCER JOURNAL FOR CLINICIANS, 2016, 66 (02) :115-132

[7]

Clinton T, 2017, RAMBAM MAIMONIDES ME, V8, DOI 10.5041/RMMJ.10314

[8] Different stages in drug development for muscle-invasive bladder cancer [J].

Ineichen, Gallus Beatus ;

Rothlisberger, Raphael ;

Johner, Kevin Fabian ;

Seiler, Roland .

TRANSLATIONAL ANDROLOGY AND UROLOGY, 2017, 6 (06) :1060-1066

[9] The association of rs710886 in lncRNA PCAT1 with bladder cancer risk in a Chinese population [J].

Lin, Yadi ;

Ge, Yuqiu ;

Wang, Yunyan ;

Ma, Gaoxiang ;

Wang, Xiaowei ;

Liu, Hanting ;

Wang, Meilin ;

Zhang, Zhengdong ;

Chu, Haiyan .

GENE, 2017, 627 :226-232

[10] Downregulation of long noncoding RNA TUG1 inhibits proliferation and induces apoptosis through the TUG1/miR-142/ZEB2 axis in bladder cancer cells [J].

Liu, Qian ;

Liu, Hui ;

Cheng, Hepeng ;

Li, Yang ;

Li, Xiaodong ;

Zhu, Chaoyang .

ONCOTARGETS AND THERAPY, 2017, 10 :2461-2471

← 1 2 3 →